Results 31 to 40 of about 10,843 (242)
A speciation study on the perturbing effects of iron chelators on the homeostasis of essential metal ions [PDF]
, 2015 A number of reports have appeared in literature calling attention to the depletion of essential metal ions during chelation therapy on beta-thalassaemia patients. We present a speciation study to determine how the iron chelators used in therapy interfere
Alberti G +6 more
core +6 more sources
International Journal of Molecular Sciences, 2022 The need for preparing new strategies for the design of emergency drug therapies against COVID-19 and similar diseases in the future is rather urgent, considering the high rate of morbidity and especially mortality associated with COVID-19, which so far ...
G. Kontoghiorghes
semanticscholar +1 more source
Chelator-facilitated removal of iron from transferrin: Relevance to combined chelation therapy [PDF]
, 2007 Current iron chelation therapy consists primarily of DFO (desferrioxamine), which has to be administered via intravenous infusion, together with deferiprone and deferasirox, which are orally-active chelators.
Devanur, LD +3 more
core +3 more sources
Incorporation by coordination and release of the iron chelator drug deferiprone from zinc-based metal–organic frameworks [PDF]
, 2013 A series of new zinc-based metal–organic framework materials has been prepared in which deferiprone is incorporated as a chelating ligand on infinite or tri-zinc secondary building units following deprotonation.
Addison +29 more
core +1 more source
Deferiprone attenuates neuropathology and improves outcome following traumatic brain injury
British Journal of Pharmacology, 2022 Traumatic brain injury (TBI) remains a leading cause of mortality and morbidity in young adults. The role of iron in potentiating neurodegeneration following TBI has gained recent interest as iron deposition has been detected in the injured brain in the ...
M. Daglas +5 more
semanticscholar +1 more source
Annals of Hematology, 2022 Patients with sickle cell disease (SCD) who undergo repeated blood transfusions often develop iron overload. Deferiprone (Ferriprox®) is an oral iron chelator indicated for the treatment of transfusional iron overload due to thalassemia syndromes and has
D. Soulières +5 more
semanticscholar +1 more source
Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression
Neurotherapeutics, 2022 Depressed individuals who carry the short allele for the serotonin-transporter-linked promotor region of the gene are more vulnerable to stress and have reduced response to first-line antidepressants such as selective serotonin reuptake inhibitors. Since
Volkan Uzungil +11 more
semanticscholar +1 more source
Population pharmacokinetics of deferiprone in healthy subjects [PDF]
British Journal of Clinical Pharmacology, 2014 AimsTo characterize the pharmacokinetics of deferiprone in healthy subjects using a model‐based approach and to assess the effect of demographic and physiological factors on drug exposure.MethodsData from 55 adult healthy subjects receiving deferiprone (solution 100 mg ml−1) were used for model building purposes.
Francesco Bellanti +2 more
openaire +3 more sources
Coordination chemistry and biology of chelators for the treatment of iron overload disorders [PDF]
, 2007 Treatment of the medical condition generally referred to as iron overload through the delivery of chelators has recently received a major boost. In 2005 Novartis gained FDA approval for the drug deferasirox, which may be taken orally.
al-Refaie +81 more
core +1 more source
International Journal of Molecular Sciences, 2022 Lead (Pb) exposure induces severe nephrotoxic effects in humans and animals. Herein, we compare the effects of two chelating agents, salinomycin and deferiprone, on Pb-induced renal alterations in mice and in the homeostasis of essential elements.
Y. Gluhcheva +10 more
semanticscholar +1 more source